Search
Eli Lilly Plans to Acquire Blood Cancer Drug Developer Ajax for Up to $2.3 Billion
20 hour ago /
Read about 0 minute
Author：小编
On April 27, 2026, Eli Lilly and Company announced its intention to acquire biopharmaceutical company Ajax Therapeutics for up to $2.3 billion in cash, aiming to expand its cancer therapy portfolio. Ajax's core investigational drug, AJ1-11095, is a once-daily oral Type II JAK2 inhibitor currently in Phase I clinical trials, targeting patients with myelofibrosis who have previously been treated with Type I JAK2 inhibitors.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
